US/UK/Canada

Share

Links

Pick a time period -
Tags ( Active)

BerGenBio announces interim biomarker and phase II clinical data with selective AXL inhibitor bemcentinib presented at ESMO

Biomarker predicts clinical benefit rate of 70% and overall response rate of 40% in second line NSCLC. Melanoma combination study reports safety and efficacy.Bergen, Norway, 22 October 2018 - BerGenBio ASA (OSE:BGBIO) announces that the company and its collaborators have presented interim clinical and biomarker data from BerGenBio’s Phase II clinical programme with bemcentinib (BGB324), a first-in-class highly selective oral AXL inhibitor, at the ESMO 2018 Congress in Munich (19 - 23 October 2018). Additionally, a pre-clinical study in myelodysplastic syndrome (MDS) was presented. The

BerGenBio ASA: Results for the First Quarter 2018

Bergen, Norway, 15 May 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, announces its results for the first quarter 2018. A presentation of the results by the Company’s management will take place today at 10.00 am CET in Oslo – details below.Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We are pleased with the progress made during Q1 2018. Patient recruitment into our global Phase II clinical proof-of-concept trials with bemcentinib is progressing well and we

BerGenBio participation at upcoming healthcare investor and life sciences industry conferences

Bergen, Norway, 14 May 2018– BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple cancer indications, will be participating at the following upcoming conferences.· 14-16 May, Bio€quity Europe 2018 (Ghent, Belgium)* · 23 May, ABG Sundal Collier Cancer Seminar (Stockholm, Sweden)* · 1 June, Sachs Immuno-Oncology BD&L and Investment Forum (Chicago, IL)* · 4 June, Norne Securities Conference (Bergen, Norway)*  · 1-5 June, 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Chicago,

BerGenBio to present overview of phase II clinical trial portfolio combining bemcentinib with KEYTRUDA at 3rd Annual Immuno-Oncology Summit Europe

Bergen, Norway, 22 March 2018 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors as a potential cornerstone of combination cancer therapy, announces that the Company will be presenting an overview of the three ongoing phase II trials combining the Company’s selective AXL inhibitor bemcentinib with the anti-PD-1 therapy KEYTRUDA at the 3rd Annual Immuno-Oncology Summit Europe, London, UK, today at 10:05-10:35 GMT.The presentation will be delivered by Dr. Julia Schoelermann, Assoc. Director Business Development &

BerGenBio ASA: Results for the Third Quarter 2017

Bergen, Norway, 17 November 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces its results for the third quarter 2017. A presentation of the results by the Company’s senior management team will take place today at 9.00 am CET in Oslo – details below.Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We are very pleased with the progress the company has made during Q3 2017. Our broad clinical development programme of Phase 2 trials with BGB324, our

Clinical Study with BGB324, BerGenBio’s Selective First-in-Class AXL Inhibitor, to be Presented at the 9th World Congress of Melanoma

Bergen, Norway, Oct 12 2017 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, announces that the clinical trial of BGB324 in combination with either MEKINIST® (trametinib) plus TAFINLAR® (dabrafenib) or KEYTRUDA® in advanced melanoma, will be presented at the 9th World Congress of Melanoma in Brisbane, Australia, October 18-21, 2017.Dr. Oddbjørn Straume, consultant oncologist at Haukeland University Hospital and Professor at the University of Bergen Centre for Cancer Biomarkers will

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media